#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Fetal Alcohol Spectrum Disorder ( FASD ) results from alcohol use during pregnancy creating lifelong functional and cognitive impairments that fall across a spectrum .
3-1	17-22	Fetal	abstract[5]	new[5]	appos	3-6[0_5]
3-2	23-30	Alcohol	substance|abstract[5]	new|new[5]	coref	3-10
3-3	31-39	Spectrum	person|abstract[5]	new|new[5]	coref	5-28[29_0]
3-4	40-48	Disorder	abstract[5]	new[5]	_	_
3-5	49-50	(	_	_	_	_
3-6	51-55	FASD	abstract	giv	coref	4-5
3-7	56-57	)	_	_	_	_
3-8	58-65	results	_	_	_	_
3-9	66-70	from	_	_	_	_
3-10	71-78	alcohol	substance|abstract[8]	giv|new[8]	coref|coref|coref|coref	7-21|7-21[40_8]|7-21|7-21[40_8]
3-11	79-82	use	abstract[8]	new[8]	_	_
3-12	83-89	during	_	_	_	_
3-13	90-99	pregnancy	event	new	coref	7-24
3-14	100-108	creating	_	_	_	_
3-15	109-117	lifelong	abstract[10]	new[10]	_	_
3-16	118-128	functional	abstract[10]	new[10]	_	_
3-17	129-132	and	abstract[10]	new[10]	_	_
3-18	133-142	cognitive	abstract[10]	new[10]	_	_
3-19	143-154	impairments	abstract[10]	new[10]	_	_
3-20	155-159	that	_	_	_	_
3-21	160-164	fall	_	_	_	_
3-22	165-171	across	_	_	_	_
3-23	172-173	a	abstract[11]	new[11]	_	_
3-24	174-182	spectrum	abstract[11]	new[11]	_	_
3-25	183-184	.	_	_	_	_

#Text=The actual prevalence of FASD is unknown , but recent estimates suggest a rate of 1.4 % – 4.4 % of the population in Alberta with 4 % identified as the best estimate in Canada .
4-1	185-188	The	abstract[12]	new[12]	coref	9-10[58_12]
4-2	189-195	actual	abstract[12]	new[12]	_	_
4-3	196-206	prevalence	abstract[12]	new[12]	_	_
4-4	207-209	of	abstract[12]	new[12]	_	_
4-5	210-214	FASD	abstract[12]|abstract	new[12]|giv	coref	5-15[24_0]
4-6	215-217	is	_	_	_	_
4-7	218-225	unknown	_	_	_	_
4-8	226-227	,	_	_	_	_
4-9	228-231	but	_	_	_	_
4-10	232-238	recent	abstract[14]	new[14]	_	_
4-11	239-248	estimates	abstract[14]	new[14]	_	_
4-12	249-256	suggest	_	_	_	_
4-13	257-258	a	abstract[15]	new[15]	_	_
4-14	259-263	rate	abstract[15]	new[15]	_	_
4-15	264-266	of	abstract[15]	new[15]	_	_
4-16	267-270	1.4	abstract[15]|quantity[16]	new[15]|new[16]	_	_
4-17	271-272	%	abstract[15]|quantity[16]	new[15]|new[16]	_	_
4-18	273-274	–	abstract[15]	new[15]	_	_
4-19	275-278	4.4	abstract[15]|quantity[17]	new[15]|new[17]	_	_
4-20	279-280	%	abstract[15]|quantity[17]	new[15]|new[17]	_	_
4-21	281-283	of	abstract[15]|quantity[17]	new[15]|new[17]	_	_
4-22	284-287	the	abstract[15]|quantity[17]|abstract[18]	new[15]|new[17]|new[18]	_	_
4-23	288-298	population	abstract[15]|quantity[17]|abstract[18]	new[15]|new[17]|new[18]	_	_
4-24	299-301	in	abstract[15]|quantity[17]|abstract[18]	new[15]|new[17]|new[18]	_	_
4-25	302-309	Alberta	abstract[15]|quantity[17]|abstract[18]|person	new[15]|new[17]|new[18]|new	coref	11-11[92_0]
4-26	310-314	with	_	_	_	_
4-27	315-316	4	quantity[20]	new[20]	_	_
4-28	317-318	%	quantity[20]	new[20]	_	_
4-29	319-329	identified	_	_	_	_
4-30	330-332	as	_	_	_	_
4-31	333-336	the	_	_	_	_
4-32	337-341	best	_	_	_	_
4-33	342-350	estimate	_	_	_	_
4-34	351-353	in	_	_	_	_
4-35	354-360	Canada	place	new	ana	5-1
4-36	361-362	.	_	_	_	_

#Text=It is thought that the vast majority of people affected are not diagnosed with the disorder either because their health problems are diagnosed under other categories or the individual does not come to the attention of diagnosticians .
5-1	363-365	It	place	giv	_	_
5-2	366-368	is	_	_	_	_
5-3	369-376	thought	_	_	_	_
5-4	377-381	that	_	_	_	_
5-5	382-385	the	person[23]	new[23]	ana	5-19[0_23]
5-6	386-390	vast	person[23]	new[23]	_	_
5-7	391-399	majority	person[23]	new[23]	_	_
5-8	400-402	of	person[23]	new[23]	_	_
5-9	403-409	people	person[23]	new[23]	_	_
5-10	410-418	affected	_	_	_	_
5-11	419-422	are	_	_	_	_
5-12	423-426	not	_	_	_	_
5-13	427-436	diagnosed	_	_	_	_
5-14	437-441	with	_	_	_	_
5-15	442-445	the	abstract[24]	giv[24]	coref	6-4[0_24]
5-16	446-454	disorder	abstract[24]	giv[24]	_	_
5-17	455-461	either	_	_	_	_
5-18	462-469	because	_	_	_	_
5-19	470-475	their	person|abstract[27]	giv|new[27]	_	_
5-20	476-482	health	abstract|abstract[27]	new|new[27]	coref	9-91
5-21	483-491	problems	abstract[27]	new[27]	_	_
5-22	492-495	are	_	_	_	_
5-23	496-505	diagnosed	_	_	_	_
5-24	506-511	under	_	_	_	_
5-25	512-517	other	abstract[28]	new[28]	_	_
5-26	518-528	categories	abstract[28]	new[28]	_	_
5-27	529-531	or	_	_	_	_
5-28	532-535	the	person[29]	giv[29]	_	_
5-29	536-546	individual	person[29]	giv[29]	_	_
5-30	547-551	does	_	_	_	_
5-31	552-555	not	_	_	_	_
5-32	556-560	come	_	_	_	_
5-33	561-563	to	_	_	_	_
5-34	564-567	the	abstract[30]	new[30]	_	_
5-35	568-577	attention	abstract[30]	new[30]	_	_
5-36	578-580	of	abstract[30]	new[30]	_	_
5-37	581-595	diagnosticians	abstract[30]|abstract	new[30]|new	_	_
5-38	596-597	.	_	_	_	_

#Text=In essence , FASD often goes unrecognized .
6-1	598-600	In	_	_	_	_
6-2	601-608	essence	_	_	_	_
6-3	609-610	,	_	_	_	_
6-4	611-615	FASD	abstract	giv	coref	8-10
6-5	616-621	often	_	_	_	_
6-6	622-626	goes	_	_	_	_
6-7	627-639	unrecognized	_	_	_	_
6-8	640-641	.	_	_	_	_

#Text=Prevention efforts have been ongoing for over two decades with a focus on broad messaging about the importance of avoiding alcohol use during pregnancy , but these efforts , while creating awareness , have not necessarily changed alcohol use behavior .
7-1	642-652	Prevention	abstract|event[34]	new|new[34]	coref|coref|coref|coref	7-27[42_34]|8-2|7-27[42_34]|8-2
7-2	653-660	efforts	event[34]	new[34]	_	_
7-3	661-665	have	_	_	_	_
7-4	666-670	been	_	_	_	_
7-5	671-678	ongoing	_	_	_	_
7-6	679-682	for	_	_	_	_
7-7	683-687	over	time[35]	new[35]	_	_
7-8	688-691	two	time[35]	new[35]	_	_
7-9	692-699	decades	time[35]	new[35]	_	_
7-10	700-704	with	time[35]	new[35]	_	_
7-11	705-706	a	time[35]|abstract[36]	new[35]|new[36]	_	_
7-12	707-712	focus	time[35]|abstract[36]	new[35]|new[36]	_	_
7-13	713-715	on	time[35]|abstract[36]	new[35]|new[36]	_	_
7-14	716-721	broad	time[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	coref	16-20[132_37]
7-15	722-731	messaging	time[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	_	_
7-16	732-737	about	time[35]|abstract[36]|abstract[37]	new[35]|new[36]|new[37]	_	_
7-17	738-741	the	time[35]|abstract[36]|abstract[37]|abstract[38]	new[35]|new[36]|new[37]|new[38]	_	_
7-18	742-752	importance	time[35]|abstract[36]|abstract[37]|abstract[38]	new[35]|new[36]|new[37]|new[38]	_	_
7-19	753-755	of	_	_	_	_
7-20	756-764	avoiding	_	_	_	_
7-21	765-772	alcohol	substance|abstract[40]	giv|giv[40]	coref|coref|coref|coref	7-38|7-39[0_40]|7-38|7-39[0_40]
7-22	773-776	use	abstract[40]	giv[40]	_	_
7-23	777-783	during	abstract[40]	giv[40]	_	_
7-24	784-793	pregnancy	abstract[40]|event	giv[40]|giv	coref	9-38
7-25	794-795	,	_	_	_	_
7-26	796-799	but	_	_	_	_
7-27	800-805	these	event[42]	giv[42]	coref	8-4[49_42]
7-28	806-813	efforts	event[42]	giv[42]	_	_
7-29	814-815	,	_	_	_	_
7-30	816-821	while	_	_	_	_
7-31	822-830	creating	_	_	_	_
7-32	831-840	awareness	abstract	new	coref	13-10[102_0]
7-33	841-842	,	_	_	_	_
7-34	843-847	have	_	_	_	_
7-35	848-851	not	_	_	_	_
7-36	852-863	necessarily	_	_	_	_
7-37	864-871	changed	_	_	_	_
7-38	872-879	alcohol	substance|abstract[46]	giv|new[46]	coref|coref	9-35|9-35
7-39	880-883	use	abstract|abstract[46]	giv|new[46]	_	_
7-40	884-892	behavior	abstract[46]	new[46]	_	_
7-41	893-894	.	_	_	_	_

#Text=Despite prevention and education efforts , the rates of FASD are thought to be much higher than previously considered , raising concerns that prevention has not been successful in reducing incidence .
8-1	895-902	Despite	_	_	_	_
8-2	903-913	prevention	abstract	giv	coref	8-24
8-3	914-917	and	_	_	_	_
8-4	918-927	education	person|event[49]	new|giv[49]	coref|coref	13-13|13-13
8-5	928-935	efforts	event[49]	giv[49]	_	_
8-6	936-937	,	_	_	_	_
8-7	938-941	the	abstract[50]	new[50]	_	_
8-8	942-947	rates	abstract[50]	new[50]	_	_
8-9	948-950	of	abstract[50]	new[50]	_	_
8-10	951-955	FASD	abstract[50]|abstract	new[50]|giv	coref	9-17[60_0]
8-11	956-959	are	_	_	_	_
8-12	960-967	thought	_	_	_	_
8-13	968-970	to	_	_	_	_
8-14	971-973	be	_	_	_	_
8-15	974-978	much	_	_	_	_
8-16	979-985	higher	_	_	_	_
8-17	986-990	than	_	_	_	_
8-18	991-1001	previously	_	_	_	_
8-19	1002-1012	considered	_	_	_	_
8-20	1013-1014	,	_	_	_	_
8-21	1015-1022	raising	_	_	_	_
8-22	1023-1031	concerns	abstract[52]	new[52]	_	_
8-23	1032-1036	that	abstract[52]	new[52]	_	_
8-24	1037-1047	prevention	abstract[52]|abstract	new[52]|giv	coref	13-16
8-25	1048-1051	has	abstract[52]	new[52]	_	_
8-26	1052-1055	not	abstract[52]	new[52]	_	_
8-27	1056-1060	been	abstract[52]	new[52]	_	_
8-28	1061-1071	successful	abstract[52]	new[52]	_	_
8-29	1072-1074	in	_	_	_	_
8-30	1075-1083	reducing	_	_	_	_
8-31	1084-1093	incidence	abstract	new	_	_
8-32	1094-1095	.	_	_	_	_

#Text=Hoyme , Kalberg , Elliot et al. indicate that the “ soaring prevalence and burden of FASD in children recently led the American Academy of Pediatrics to stress the following : no amount of alcohol intake during pregnancy can be considered safe ; there is no safe trimester to drink alcohol ; all forms of alcohol pose a similar risk ; and binge drinking poses a dose-related risk to the fetus ” ( p. 2 ) and , as noted above , many cases of FASD simply go unrecognized by health and helping professionals .
9-1	1096-1101	Hoyme	person	new	appos	9-3
9-2	1102-1103	,	_	_	_	_
9-3	1104-1111	Kalberg	person	giv	appos	9-5
9-4	1112-1113	,	_	_	_	_
9-5	1114-1120	Elliot	person	giv	_	_
9-6	1121-1123	et	_	_	_	_
9-7	1124-1127	al.	_	_	_	_
9-8	1128-1136	indicate	_	_	_	_
9-9	1137-1141	that	_	_	_	_
9-10	1142-1145	the	abstract[58]	giv[58]	coref	10-25[0_58]
9-11	1146-1147	“	abstract[58]	giv[58]	_	_
9-12	1148-1155	soaring	abstract[58]	giv[58]	_	_
9-13	1156-1166	prevalence	abstract[58]	giv[58]	_	_
9-14	1167-1170	and	_	_	_	_
9-15	1171-1177	burden	abstract[59]	new[59]	_	_
9-16	1178-1180	of	abstract[59]	new[59]	_	_
9-17	1181-1185	FASD	abstract[59]|abstract[60]	new[59]|giv[60]	coref	9-86[0_60]
9-18	1186-1188	in	abstract[59]|abstract[60]	new[59]|giv[60]	_	_
9-19	1189-1197	children	abstract[59]|abstract[60]|person	new[59]|giv[60]|new	_	_
9-20	1198-1206	recently	_	_	_	_
9-21	1207-1210	led	_	_	_	_
9-22	1211-1214	the	organization[62]	new[62]	_	_
9-23	1215-1223	American	organization[62]	new[62]	_	_
9-24	1224-1231	Academy	organization[62]	new[62]	_	_
9-25	1232-1234	of	organization[62]	new[62]	_	_
9-26	1235-1245	Pediatrics	organization[62]	new[62]	_	_
9-27	1246-1248	to	_	_	_	_
9-28	1249-1255	stress	_	_	_	_
9-29	1256-1259	the	event[63]	new[63]	_	_
9-30	1260-1269	following	event[63]	new[63]	_	_
9-31	1270-1271	:	event[63]	new[63]	_	_
9-32	1272-1274	no	event[63]|abstract[64]	new[63]|new[64]	_	_
9-33	1275-1281	amount	event[63]|abstract[64]	new[63]|new[64]	_	_
9-34	1282-1284	of	event[63]|abstract[64]	new[63]|new[64]	_	_
9-35	1285-1292	alcohol	event[63]|abstract[64]|substance|event[66]	new[63]|new[64]|giv|new[66]	coref|coref	9-51|9-51
9-36	1293-1299	intake	event[63]|abstract[64]|event[66]	new[63]|new[64]|new[66]	_	_
9-37	1300-1306	during	event[63]|abstract[64]|event[66]	new[63]|new[64]|new[66]	_	_
9-38	1307-1316	pregnancy	event[63]|abstract[64]|event[66]|event	new[63]|new[64]|new[66]|giv	_	_
9-39	1317-1320	can	event[63]	new[63]	_	_
9-40	1321-1323	be	event[63]	new[63]	_	_
9-41	1324-1334	considered	event[63]	new[63]	_	_
9-42	1335-1339	safe	event[63]	new[63]	_	_
9-43	1340-1341	;	_	_	_	_
9-44	1342-1347	there	_	_	_	_
9-45	1348-1350	is	_	_	_	_
9-46	1351-1353	no	substance[68]	new[68]	_	_
9-47	1354-1358	safe	substance[68]	new[68]	_	_
9-48	1359-1368	trimester	substance[68]	new[68]	_	_
9-49	1369-1371	to	_	_	_	_
9-50	1372-1377	drink	_	_	_	_
9-51	1378-1385	alcohol	substance	giv	coref	9-56
9-52	1386-1387	;	_	_	_	_
9-53	1388-1391	all	substance[70]	new[70]	_	_
9-54	1392-1397	forms	substance[70]	new[70]	_	_
9-55	1398-1400	of	substance[70]	new[70]	_	_
9-56	1401-1408	alcohol	substance[70]|substance	new[70]|giv	_	_
9-57	1409-1413	pose	_	_	_	_
9-58	1414-1415	a	abstract[72]	new[72]	coref	9-66[74_72]
9-59	1416-1423	similar	abstract[72]	new[72]	_	_
9-60	1424-1428	risk	abstract[72]	new[72]	_	_
9-61	1429-1430	;	_	_	_	_
9-62	1431-1434	and	_	_	_	_
9-63	1435-1440	binge	event	new	_	_
9-64	1441-1449	drinking	_	_	_	_
9-65	1450-1455	poses	_	_	_	_
9-66	1456-1457	a	abstract[74]	giv[74]	_	_
9-67	1458-1470	dose-related	abstract[74]	giv[74]	_	_
9-68	1471-1475	risk	abstract[74]	giv[74]	_	_
9-69	1476-1478	to	abstract[74]	giv[74]	_	_
9-70	1479-1482	the	abstract[74]|object[75]	giv[74]|new[75]	_	_
9-71	1483-1488	fetus	abstract[74]|object[75]	giv[74]|new[75]	_	_
9-72	1489-1490	”	_	_	_	_
9-73	1491-1492	(	_	_	_	_
9-74	1493-1495	p.	abstract[76]	new[76]	_	_
9-75	1496-1497	2	abstract[76]	new[76]	_	_
9-76	1498-1499	)	_	_	_	_
9-77	1500-1503	and	_	_	_	_
9-78	1504-1505	,	_	_	_	_
9-79	1506-1508	as	_	_	_	_
9-80	1509-1514	noted	_	_	_	_
9-81	1515-1520	above	_	_	_	_
9-82	1521-1522	,	_	_	_	_
9-83	1523-1527	many	abstract[77]	new[77]	_	_
9-84	1528-1533	cases	abstract[77]	new[77]	_	_
9-85	1534-1536	of	abstract[77]	new[77]	_	_
9-86	1537-1541	FASD	abstract[77]|abstract	new[77]|giv	coref	11-1
9-87	1542-1548	simply	_	_	_	_
9-88	1549-1551	go	_	_	_	_
9-89	1552-1564	unrecognized	_	_	_	_
9-90	1565-1567	by	_	_	_	_
9-91	1568-1574	health	abstract	giv	_	_
9-92	1575-1578	and	_	_	_	_
9-93	1579-1586	helping	_	_	_	_
9-94	1587-1600	professionals	person	new	_	_
9-95	1601-1602	.	_	_	_	_

#Text=We are cautious with this data , as , given that screening and diagnostic criteria and methods are changing , this may confound the prevalence data .
10-1	1603-1605	We	person	acc	_	_
10-2	1606-1609	are	_	_	_	_
10-3	1610-1618	cautious	_	_	_	_
10-4	1619-1623	with	_	_	_	_
10-5	1624-1628	this	abstract[82]	new[82]	coref	10-24[88_82]
10-6	1629-1633	data	abstract[82]	new[82]	_	_
10-7	1634-1635	,	_	_	_	_
10-8	1636-1638	as	_	_	_	_
10-9	1639-1640	,	_	_	_	_
10-10	1641-1646	given	_	_	_	_
10-11	1647-1651	that	_	_	_	_
10-12	1652-1661	screening	abstract	new	ana	10-21
10-13	1662-1665	and	_	_	_	_
10-14	1666-1676	diagnostic	abstract[84]	new[84]	_	_
10-15	1677-1685	criteria	abstract[84]	new[84]	_	_
10-16	1686-1689	and	_	_	_	_
10-17	1690-1697	methods	abstract	new	_	_
10-18	1698-1701	are	_	_	_	_
10-19	1702-1710	changing	_	_	_	_
10-20	1711-1712	,	_	_	_	_
10-21	1713-1717	this	abstract	giv	_	_
10-22	1718-1721	may	_	_	_	_
10-23	1722-1730	confound	_	_	_	_
10-24	1731-1734	the	abstract[88]	giv[88]	coref	15-5[0_88]
10-25	1735-1745	prevalence	abstract|abstract[88]	giv|giv[88]	_	_
10-26	1746-1750	data	abstract[88]	giv[88]	_	_
10-27	1751-1752	.	_	_	_	_

#Text=FASD is a clearly established priority for the province of Alberta , Canada , which is where the research reported here was conducted .
11-1	1753-1757	FASD	abstract	giv	coref	11-3[90_0]
11-2	1758-1760	is	_	_	_	_
11-3	1761-1762	a	abstract[90]	giv[90]	coref	12-10[0_90]
11-4	1763-1770	clearly	abstract[90]	giv[90]	_	_
11-5	1771-1782	established	abstract[90]	giv[90]	_	_
11-6	1783-1791	priority	abstract[90]	giv[90]	_	_
11-7	1792-1795	for	abstract[90]	giv[90]	_	_
11-8	1796-1799	the	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-9	1800-1808	province	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-10	1809-1811	of	abstract[90]|place[91]	giv[90]|new[91]	_	_
11-11	1812-1819	Alberta	abstract[90]|place[91]|person[92]	giv[90]|new[91]|giv[92]	coref	12-7[0_92]
11-12	1820-1821	,	abstract[90]|place[91]|person[92]	giv[90]|new[91]|giv[92]	_	_
11-13	1822-1828	Canada	abstract[90]|place[91]|person[92]	giv[90]|new[91]|giv[92]	_	_
11-14	1829-1830	,	_	_	_	_
11-15	1831-1836	which	_	_	_	_
11-16	1837-1839	is	_	_	_	_
11-17	1840-1845	where	_	_	_	_
11-18	1846-1849	the	abstract[93]	new[93]	coref	14-1[115_93]
11-19	1850-1858	research	abstract[93]	new[93]	_	_
11-20	1859-1867	reported	_	_	_	_
11-21	1868-1872	here	_	_	_	_
11-22	1873-1876	was	_	_	_	_
11-23	1877-1886	conducted	_	_	_	_
11-24	1887-1888	.	_	_	_	_

#Text=In 2008 , the Government of Alberta implemented an FASD 10-Year Strategic Plan .
12-1	1889-1891	In	_	_	_	_
12-2	1892-1896	2008	time	new	_	_
12-3	1897-1898	,	_	_	_	_
12-4	1899-1902	the	organization[95]	new[95]	_	_
12-5	1903-1913	Government	organization[95]	new[95]	_	_
12-6	1914-1916	of	organization[95]	new[95]	_	_
12-7	1917-1924	Alberta	organization[95]|place	new[95]|giv	coref	15-24
12-8	1925-1936	implemented	_	_	_	_
12-9	1937-1939	an	abstract[99]	new[99]	coref	13-6[101_99]
12-10	1940-1944	FASD	organization|abstract[99]	giv|new[99]	coref	13-37
12-11	1945-1952	10-Year	abstract[99]	new[99]	_	_
12-12	1953-1962	Strategic	abstract|abstract[99]	new|new[99]	_	_
12-13	1963-1967	Plan	abstract[99]	new[99]	_	_
12-14	1968-1969	.	_	_	_	_

#Text=The first two pillars of that plan focus upon public awareness and education strategies and prevention , while the other pillars look at assessment and diagnosis , support for caregivers , and the presence of an FASD learning organization .
13-1	1970-1973	The	abstract[100]	new[100]	coref	13-19[106_100]
13-2	1974-1979	first	abstract[100]	new[100]	_	_
13-3	1980-1983	two	abstract[100]	new[100]	_	_
13-4	1984-1991	pillars	abstract[100]	new[100]	_	_
13-5	1992-1994	of	abstract[100]	new[100]	_	_
13-6	1995-1999	that	abstract[100]|abstract[101]	new[100]|giv[101]	_	_
13-7	2000-2004	plan	abstract[100]|abstract[101]	new[100]|giv[101]	_	_
13-8	2005-2010	focus	_	_	_	_
13-9	2011-2015	upon	_	_	_	_
13-10	2016-2022	public	abstract[102]	giv[102]	coref	14-5[116_102]
13-11	2023-2032	awareness	abstract[102]	giv[102]	_	_
13-12	2033-2036	and	_	_	_	_
13-13	2037-2046	education	person|abstract[104]	giv|new[104]	_	_
13-14	2047-2057	strategies	abstract[104]	new[104]	_	_
13-15	2058-2061	and	_	_	_	_
13-16	2062-2072	prevention	abstract	giv	_	_
13-17	2073-2074	,	_	_	_	_
13-18	2075-2080	while	_	_	_	_
13-19	2081-2084	the	abstract[106]	giv[106]	_	_
13-20	2085-2090	other	abstract[106]	giv[106]	_	_
13-21	2091-2098	pillars	abstract[106]	giv[106]	_	_
13-22	2099-2103	look	_	_	_	_
13-23	2104-2106	at	_	_	_	_
13-24	2107-2117	assessment	event	new	_	_
13-25	2118-2121	and	_	_	_	_
13-26	2122-2131	diagnosis	event	new	_	_
13-27	2132-2133	,	_	_	_	_
13-28	2134-2141	support	abstract[109]	new[109]	_	_
13-29	2142-2145	for	abstract[109]	new[109]	_	_
13-30	2146-2156	caregivers	abstract[109]|person	new[109]|new	_	_
13-31	2157-2158	,	_	_	_	_
13-32	2159-2162	and	_	_	_	_
13-33	2163-2166	the	abstract[111]	new[111]	_	_
13-34	2167-2175	presence	abstract[111]	new[111]	_	_
13-35	2176-2178	of	abstract[111]	new[111]	_	_
13-36	2179-2181	an	abstract[111]|organization[114]	new[111]|new[114]	ana	15-1[0_114]
13-37	2182-2186	FASD	abstract[111]|abstract|organization[114]	new[111]|giv|new[114]	coref	15-22[125_0]
13-38	2187-2195	learning	abstract[111]|abstract|organization[114]	new[111]|new|new[114]	_	_
13-39	2196-2208	organization	abstract[111]|organization[114]	new[111]|new[114]	_	_
13-40	2209-2210	.	_	_	_	_

#Text=This research looks at public awareness , which is part of the first pillar .
14-1	2211-2215	This	abstract[115]	giv[115]	_	_
14-2	2216-2224	research	abstract[115]	giv[115]	_	_
14-3	2225-2230	looks	_	_	_	_
14-4	2231-2233	at	_	_	_	_
14-5	2234-2240	public	abstract[116]	giv[116]	coref	15-19[124_116]
14-6	2241-2250	awareness	abstract[116]	giv[116]	_	_
14-7	2251-2252	,	_	_	_	_
14-8	2253-2258	which	_	_	_	_
14-9	2259-2261	is	_	_	_	_
14-10	2262-2266	part	_	_	_	_
14-11	2267-2269	of	_	_	_	_
14-12	2270-2273	the	abstract[117]	new[117]	_	_
14-13	2274-2279	first	abstract[117]	new[117]	_	_
14-14	2280-2286	pillar	abstract[117]	new[117]	_	_
14-15	2287-2288	.	_	_	_	_

#Text=It uses a secondary data analysis of the 2011 and 2017 datasets to examine characteristics and changes in public awareness of FASD in Alberta .
15-1	2289-2291	It	organization	giv	_	_
15-2	2292-2296	uses	_	_	_	_
15-3	2297-2298	a	abstract[120]	new[120]	_	_
15-4	2299-2308	secondary	abstract[120]	new[120]	_	_
15-5	2309-2313	data	abstract|abstract[120]	giv|new[120]	_	_
15-6	2314-2322	analysis	abstract[120]	new[120]	_	_
15-7	2323-2325	of	abstract[120]	new[120]	_	_
15-8	2326-2329	the	abstract[120]|object[121]	new[120]|new[121]	_	_
15-9	2330-2334	2011	abstract[120]|object[121]	new[120]|new[121]	_	_
15-10	2335-2338	and	abstract[120]|object[121]	new[120]|new[121]	_	_
15-11	2339-2343	2017	abstract[120]|object[121]	new[120]|new[121]	_	_
15-12	2344-2352	datasets	abstract[120]|object[121]	new[120]|new[121]	_	_
15-13	2353-2355	to	_	_	_	_
15-14	2356-2363	examine	_	_	_	_
15-15	2364-2379	characteristics	abstract	new	_	_
15-16	2380-2383	and	_	_	_	_
15-17	2384-2391	changes	abstract	new	_	_
15-18	2392-2394	in	_	_	_	_
15-19	2395-2401	public	abstract[124]	giv[124]	_	_
15-20	2402-2411	awareness	abstract[124]	giv[124]	_	_
15-21	2412-2414	of	abstract[124]	giv[124]	_	_
15-22	2415-2419	FASD	abstract[124]|abstract[125]	giv[124]|giv[125]	coref	16-12[0_125]
15-23	2420-2422	in	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
15-24	2423-2430	Alberta	abstract[124]|abstract[125]|place	giv[124]|giv[125]|giv	_	_
15-25	2431-2432	.	_	_	_	_

#Text=The present project looks to understand the degree of awareness of FASD , which can assist in understanding whether the messaging is at least impacting at that level .
16-1	2433-2436	The	abstract[127]	new[127]	_	_
16-2	2437-2444	present	abstract[127]	new[127]	_	_
16-3	2445-2452	project	abstract[127]	new[127]	_	_
16-4	2453-2458	looks	_	_	_	_
16-5	2459-2461	to	_	_	_	_
16-6	2462-2472	understand	_	_	_	_
16-7	2473-2476	the	abstract[128]	new[128]	_	_
16-8	2477-2483	degree	abstract[128]	new[128]	_	_
16-9	2484-2486	of	abstract[128]	new[128]	_	_
16-10	2487-2496	awareness	abstract[128]|abstract[129]	new[128]|new[129]	_	_
16-11	2497-2499	of	abstract[128]|abstract[129]	new[128]|new[129]	_	_
16-12	2500-2504	FASD	abstract[128]|abstract[129]|abstract	new[128]|new[129]|giv	_	_
16-13	2505-2506	,	_	_	_	_
16-14	2507-2512	which	_	_	_	_
16-15	2513-2516	can	_	_	_	_
16-16	2517-2523	assist	_	_	_	_
16-17	2524-2526	in	_	_	_	_
16-18	2527-2540	understanding	abstract	new	_	_
16-19	2541-2548	whether	_	_	_	_
16-20	2549-2552	the	abstract[132]	giv[132]	_	_
16-21	2553-2562	messaging	abstract[132]	giv[132]	_	_
16-22	2563-2565	is	_	_	_	_
16-23	2566-2568	at	_	_	_	_
16-24	2569-2574	least	_	_	_	_
16-25	2575-2584	impacting	_	_	_	_
16-26	2585-2587	at	_	_	_	_
16-27	2588-2592	that	abstract[133]	new[133]	_	_
16-28	2593-2598	level	abstract[133]	new[133]	_	_
16-29	2599-2600	.	_	_	_	_
